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INTRODUCT ION
Care of critically ill patients requires frequent adjust-
ments of therapy based on clinical conditions and
intervening pathophysiological modifications which
affect pharmacokinetics.
Sepsis and polytrauma are two of the most life-
threatening conditions seen in Intensive Care Unit (ICU),
both involving significant modifications of organ-specific
and systemic homeostasis. The management of patients
with sepsis is difficult as underlined by the EURICUS
studies that describe the critical role of the length of stay
(LOS) for the development of organ failure, with an high
impact on mortality rate after discharge from the ICU
[1,2]. Indeed, sepsis can occur in critically ill patients as
a nosocomial infection, often related with the duration of
hospitalization. Sepsis is defined as a systemic inflam-
matory response syndrome (SIRS) to a proved (or
suspected) infection, that results in the alteration of the
coagulation system and the microcirculation, with
failure of organs/tissues perfusion, and dysregulation of
the immune system [3–5]. In severe sepsis or septic
shock, pathophysiological changes partially or com-
pletely modify pharmacokinetic parameters, resulting
in an escalating approach to the number and, often,
dosing of administered drugs [6].
The systemic inflammatory response, commonly seen
in patients with major trauma (MT), is induced and
sustained by the ensuing cascade of inflammatory
mediators, which can determine flow-misdistribution
and peripheral hypoperfusion [7]. The extent of inflam-
mation in patients with trauma markedly varies accord-
ing to the type of injury; bacterial or fungal colonization
of wounded organs may result in severe infection, sepsis,
and septic shock.
Currently, the most relevant therapeutic interventions
in ICU are targeted to the prevention of organ failure,
limitation of adverse reactions and LOS. In this perspec-
tive, rational drug adjustments, based on pharmaco-
kinetic and pharmacodynamic changes that characterize
sepsis or MT, often dictate the outcome of a critically ill
patient. The changed physiology and, consequently, the
pharmacokinetic parameters, could indeed alter the
efficacy and the safety of drugs at the dosage usually
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ABSTRACT
Critically ill patients, not infrequently present alterations of physiological parameters
that determine the success/failure of therapeutic interventions as well as the final
outcome. Sepsis and polytrauma are two of the most common and complex
syndromes occurring in Intensive Care Unit (ICU) and affect drug absorption,
disposition, metabolism and elimination. Pharmacological management of ICU
patients requires consideration of the unique pharmacokinetics associated with these
clinical conditions and the likely occurrence of drug interaction. Rational adjustment
in drug choice and dosing contributes to the appropriateness of treatment of those
patients.
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prescribed, potentially producing side-effects and/or ther-
apeutic failure.
PATHOPHYS IOLOGY OF SEPS IS
The definition of sepsis includes suspected or demon-
strated infection, in a patient with clinical signs of SIRS
(fever or hypothermia, bradycardia or tachycardia,
tachypnea, leukocytosis or leucopenia or circulating
immature forms) [3]. Sepsis is classified as severe when
induces organ dysfunction or tissue hypoperfusion,
whereas septic shock is the evolution of severe sepsis,
with systemic hypoperfusion [8]. Septic shock and multi-
organ failure (MOF) are the most common causes of
death in patients with sepsis. Mortality rate associated
with severe sepsis is up to 30%, with a pick of 70% for
septic shock [6,9–11].
Sepsis is characterized by a complex, and still not
completely understood, interaction between the immune
system (innate and adaptive), the coagulation system,
inflammatory mediators, and microorganisms [4–6].
Thus, sepsis can be defined as a maladaptive response
of the host to a bacterial-fungal–viral infection, the
severity of which depends both from the pre-morbid
health condition of the host and the virulence of the
microorganism involved.
In the initial phase of the host-microorganism interac-
tion, the innate immune system plays a pivotal role,
mainly through the activation of toll-like receptors (TLRs)
[12,13] and subsequent synthesis and release of pro-
inflammatory molecules, such as tumor necrosis factor a
(TNF-a), interleukin-6 (IL-6) and interleukin-1b (IL-1b)
(Table I). In sepsis, the increasing expression of procalci-
tonin (PCT) is considered a diagnostic and a prognostic
marker, although its role in SIRS and sepsis has still to be
clarified [14,15] (Table I). PCT production is induced by
bacterial lipopolysaccharide and pro-inflammatory cyto-
kines in different cells, such as hepatocytes and human
peripheral blood mononuclear cells [16,17]. As PCT, the
expression of calcitonin gene-related peptide appears to be
increased in SIRS and sepsis [18–20], suggesting an
important role of this potent vasodilator agent [21],
in refractory septic shock. Activation of neutrophils,
monocytes/macrophages and lymphocytes produces in-
jury to the endothelium, with development of increased
endothelial permeability, accumulation of plasma pro-
teins and fluids into the interstitium and in usually fluid-
free anatomical cavities (e.g., pleural cavity) (Table I).
Moreover, activation of endothelial cells leads to the
production and release of nitric oxide (NO), one of themost
potent vasodilator and a central player in the pathogenesis
of septic shock [22] (Table I).
The immunosuppression associated with sepsis facili-
tates microorganism colonization and diffusion and is
sustained by complex mechanisms, including the evolu-
tion of T lymphocytes from a Th1 phenotype (producing
pro-inflammatory mediators), to a Th2 phenotype (pro-
ducing anti-inflammatory cytokines) [6,23]. Decreased
number of immune cells (T and B lymphocytes, dendritic
cells) by apoptosis has also been correlated with the
activity of the disease [24] and the outcome [5,25,26].
Mitochondrial dysfunction, with failure to produce ATP,
is also considered an important pathological features in
multi-organ dysfunction [5,7,27] (Table I).
The over-production of reactive nitrogen species (RNS)
and reactive oxygen species (ROS), associated with a
Table I Physiopathologic features of sepsis, major trauma and
head trauma.
Sepsis
Major
trauma
Head
trauma
SIRS criteria
[3,37]
Present Present May occur
Activation of innate immune
system
[3,37,44,45]
Yes Yes Yes
IL-1 b, IL-6, TNF-a
over-production
[4,5,7,42]
Yes Yes Yes
PCT level increase
[14,15]
Yes May occur May occur
Capillary leakage
[4,5,7,33,34]
Present May occur May occur
Coagulation and hemostasis
alteration
[4,5,7,30–32]
Yes Yes Yes
Interstitial edema
[4,5,7]
Present May occur May occur
Release of NO
[4,5,7,40]
Yes May occur May occur
Mitochondrial dysfunction and
ATP production impairment
[5,7,27]
Yes May occur May occur
RNS and ROS over-production
[4,5,7,28,39,40]
Yes Yes Yes
Apoptosis
[4,5,7,25,26]
Yes May occur May occur
Cell lysis and necrosis
[4,5,7]
May occur Yes Yes
SIRS, systemic inflammatory response syndrome; PCT, procalcitonin; TNF-a,
tumor necrosis factor a; IL-6, interleukin-6; IL-1b, interleukin-1b; NO, nitric
oxide; RNS, reactive nitrogen species; ROS, reactive oxygen species.
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reduction or depletion of antioxidant defense systems
(i.e., glutathione) of the host, also play a role in the
pathogenesis of MOF [28,29] and the increase in pro-
coagulant activity observed in sepsis [30] (Table I). The
imbalance between coagulation and anti-coagulation
systems is also supported by the suppression of anti-
hemostatic factors induced by inflammatory mediators
(IL-6, TNF-a) [31]. Moreover, sepsis is characterized by a
high consumption of protein C, associated with low levels
of protein S and antithrombin III [32]. The excess
procoagulant activity is implicated in failure of micro-
circulation and consequent tissue hypoperfusion
[5,6,33]. Endothelial dysfunction and microcirculation
impairment have been directly correlated to multi-organ
dysfunction syndrome (MODS) and clinical outcome [34].
PATHOPHYS IOLOGY OF TRAUMA
Major trauma is the first cause of death in young people
[7,35,36]. Death can occur as a consequence of direct
physical injury or late complications, such as infections
(microbial colonization of exposed wounds) and/or organ
failure.
The injury to organs, soft tissues and bones determines
a host systemic inflammatory reaction which can be
defined, as well as in sepsis, as SIRS [3,37] (Table I). Cell
lysis results in the release of endogenous antigens which
stimulate coagulation, complement cascade, and chemo-
taxis of circulating adaptive immune cells, with over-
activation of leukocytes, monocytes/macrophages, and
natural killer cells leading, in the most severe cases, to
the development of MODS and MOF [7]. Bleeding and
loss of tissues also contribute to the fall in the perfusion
of organs.
An extensive injury results in massive production of
TNF-a, interferon (IFN)-c, IL-1b, IL-6 as also adhesion
molecules, acute phase proteins, arachidonic acid meta-
bolites (Table I). Like in sepsis, the expression of PCT
could raise in severe trauma [14] (Table I). Adhesion and
accumulation of neutrophils, and other inflammatory
cells, in the damaged tissue play a pivotal role in the
development of secondary organ failure [38] through the
over-production and activation of proteases, ROS and
RNS [7,39,40] (Table I).
In MT, blood loss can be an important pathological
event. Hemorrhage can occur both through open-flesh
wounds and/or through close fracture of bones (e.g., a
severe pelvic bone fracture can determine an hemor-
rhagic flow of up to 5 L). A profuse blood loss affects
oxygen delivery and transportation of nutrients to the
peripheral tissues. Intravascular volume support
includes infusion of crystalloids and colloidal solutions
[41] and, based on the estimated loss of blood volume,
transfusions of erythrocytes, platelets and plasma,
depending on the hemoglobin level and coagulation
tests. The fall in arterial pressure, consequent to the
blood loss, increases the production of endogenous
vasoactive agents. The level of vasoconstriction
observed in a trauma patient is higher than expected,
as a consequence of the stress reaction to the injury;
therefore, further stimulations, oriented to maintain a
normal mean arterial pressure, can cause an excess of
peripheral vasoconstriction with a fall in perfusion.
Thus, microcirculation perfusion failure may derive
directly from the blood loss and indirectly from the
inflammation and the vasoconstriction induced by
endogenous amines produced in the stress neuro-
hormonal reaction [7].
Pathophysiology of head trauma
Special attention should be directed to patients with head
trauma. A primary brain damage results from forces
directly applied to the skull, leading to either focal or
diffuse injury patterns, which could have a very poor
prognosis. The injury to the brain induces an acute
reaction in the cells of central nervous system (neurons,
astrocytes, microglia), with the production of pro-
inflammatory mediators and local inflammation [42]
(Table I). Moreover, as a direct consequence of the
trauma, the blood–brain barrier is interrupted and
systemic inflammatory mediators produced by distant
wounded body parts, can come in contact with the brain,
starting an ‘inflammatory communication’ between
the central nervous system (CNS) and the periphery.
The secretion of cytokines and chemokines maintains the
inflammatory response, with the development of a
neurodegenerative disease of the brain and of spinal
cord injury [43–46] (Table I). Several cytokines are
involved in neuroinflammation, included IFN-c, TNF-a,
IL-1a, IL-1b, and IL-6 [42], that seems to have a
neuroprotective role as well [47]. The release of prote-
ases and the production of ROS contribute to damage the
blood–brain barrier and to the development of cerebral
inflammatory edema [48–50] (Table I).
PHARMACOLOGICAL ADJUSTMENTS
IN THE CR IT ICALLY I LL PAT IENT
As a consequence of the pathophysiological modifica-
tions that occur in patients with sepsis or MT, drug
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pharmacokinetics and pharmacodynamics may be heav-
ily altered, with major concern for therapy management
[51–53].
Absorption and distribution
Oral absorption could be critically compromised as a
result of the impairment of gastrointestinal peristalsis.
Moreover, patients with intestinal infection or ischemia
often undergo parenteral nutrition. Cardiac failure could
also impair the intestinal absorption of drugs, both for
reduced perfusion of organ and congestion of the venous
system [51,52]. Modifications of skin and muscle perf-
usion and variation in body water content, frequently
alter the first part of the absorption curve of drugs
administered by intramuscular, subcutaneous, or trans-
dermal routes. At the present time, very few experimen-
tal data exist on pharmacokinetic changes of drugs in
critically ill patients, and no evidence-based protocols are
available to guide the physician.
Intravenous (i.v.) administration is the preferred route
in ICU patients who often require invasive intravascular
devices, such as central venous catheters. The i.v. route
assures the highest biological availability of drugs, which
is critical especially for antimicrobial agents [54,55], and
allows rapid correction of the dosage, particularly
important in patients who require hemodynamic support
with vasoactive-inotrope agents [56].
Role of nutraceutical interventions
Recently, the importance of nutraceutical interventions
has been emphasized [57–59]. Enteral nutrition should
be preferred even in patients with impaired gastric
emptying, in which prokinetic drugs and a correct body
positioning can improve peristalsis [60,61]. Indeed,
maintenance of the physiological bacterial flora has
been related with the preservation and homeostasis of
the gastrointestinal mucosa. Bacterial translocation has
been found to be lower in critical patients receiving
enteral nutrition, with the addition of omega-3 (eicosa-
pentaenoic and docosahexaenoic) fatty acids, glutamine,
antioxidants [57,58,62], nucleotides, prebiotic and pro-
biotic supplements [63], whereas the role of arginine
supplements in sepsis is still controversial [64,65].
Modification of the gastrointestinal system
An intra-abdominal pressure (IAP) increase over
12 mmHg should be considered pathological, and it
has been defined as intra-abdominal hypertension (IAH)
[66]. Risk-factors for the development of IAH include
abdominal trauma, excess of fluid replacement, sepsis,
mechanical ventilation (MV) with high positive end-
expiratory pressure (PEEP), moderate to severe hypo-
thermia, bleeding into the abdominal cavity, liver failure
with ascites. The increased IAP interferes with venous
return to the right heart and gut mucosa perfusion (with
augmented risk of intestinal sepsis and malabsorption),
and impairs portal vein flow to the liver. All these
modifications might contribute to alter the pharmaco-
kinetics of orally administered drugs. In addition, distri-
bution of i.v. drugs may be altered by decreased plasma
protein production (liver failure) and/or protein intake
[53]. Moreover, pathologic IAP can contribute to kidney
hypoperfusion with subsequent renal impairment and
reduced drug clearance.
Support to the circulation
Maintenance of an adequate tissue perfusion is of
paramount importance in critically ill patients, which
often requires exogenous amines (norepinephrine, dobu-
tamine), vasoconstrictor agents (vasopressin), and fluid
replacement (colloids, crystalloids) [6]. The rate of
infusion of vasoactive-inotrope agents should be contin-
uously adjusted to guarantee a suitable peripheral
perfusion, as desensitization and down-regulation of
adrenergic receptors usually require a progressive
increase in dosage [67]. However, high dosage or long-
term hemodynamic support produces a prolonged vaso-
constriction of the capillary bed. Consequently, the
maintenance of an adequate cardiac output with amine
support should be integrated with rational fluid replace-
ment therapy, to avoid systemic hypoperfusion [41]. In
fact, the impairment of tissue perfusion could interfere
with drug pharmacokinetics in many ways: increase in
tissue pH, intestinal malabsorption, muscle-skin misdis-
tribution. On the other hand, an excess of fluid replace-
ment could induce a different set of complications:
change in transportation and distribution of i.v. admin-
istered drugs because of hemodilution, decreased plasma
protein binding rate, fluid shift in the so-called ‘third
space,’ increase in IAP [53]. Based on these consider-
ations, a need of prolonged hemodynamic support can
heavily modify the results (in terms of efficacy and/or
side-effects) of other pharmacological interventions.
Effects of lung injury and mechanical ventilation
ICU patients often require MV with PEEP support. PEEP
is used to recruit or stabilize lung alveolar units,
especially in situations like inhalation, post-contusive
lung injury, Acute Lung Injury/Adult Respiratory Dis-
tress Syndrome (ALI/ARDS), Transfusion Related Lung
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Injury (TRALI), pneumonia. A correct management of
ventilatory support includes weaning the patient from
MV as soon as clinical conditions improve. Indeed,
prolonged MV and longer ICU stay are related with the
development of complications, such as ventilation asso-
ciated pneumonia [68] and the polyneuropathy/myop-
athy of critically ill patient, known as ‘critical illness’
[69]. Artificial ventilation produces alteration of venous
return to the hearth, cardiac output, renal and liver
blood flow [70], with direct consequences on the
pharmacokinetics of drugs administered [71]. The appli-
cation of continuous pressure by PEEP on diaphragm
and thoracic vessels causes impairment of abdominal
perfusion of organ. Reduced splanchnic venous flow
during PEEP ventilation interferes with the function of
intestinal mucosa, and reduces the absorption of proteins
and orally administered drugs [53].
Experimental data show that during MV, pulmonary
lymphatic flow can be decreased, with consequent fluid
shift in the interstitial space and increment of intra-
pulmonary shunt [72,73]. The importance of these
phenomena in humans remains difficult to establish, but
it could be supposed that the distribution of drugs might
be influenced by both the extravascular fluid shift and
the intra-pulmonary shunt, with a possible alteration in
dose/effective concentration.
Sepsis, pneumonia, TRALI and pulmonary traumamay
all result in ARDS, an acute inflammatory process of the
lung [74,75]. Patients with ARDS should undergo MV
based on small tidal volumes to avoid barotrauma, and to
reduce the rate of alveolar stretching [76]. In these
patients, the use of inhaled nitric oxide (NO) could be taken
into consideration to produce bronchodilatation and to
reduce pulmonary vascular resistance, with improvement
of lung perfusion and, consequently, a better distribution
of intravenously administered drugs [77].
Hepatic metabolism and drug interactions
Hepatic failure can occur as a consequence of decreased
perfusion and oxygen delivery to the organ during severe
sepsis/septic shock, or, in trauma patients, as a direct
injury to the abdominal wall. Fall in liver function
produces alteration in all phases of drug pharmaco-
kinetic, mainly in drug transportation and metaboliza-
tion.
Drug hepatic clearance is defined as the volume of
blood which is cleared from the molecule per unit of time
[78]. The liver participates to drug pharmacokinetic at
multiple levels: transportation of the drug through the
portal vein flow, control of the free fraction of drug in
blood, metabolism of the molecule, and excretion
through the bile ducts. All these steps could be altered
in septic patients. The acute phase reaction to a stressful
event produces a decrease in liver enzymatic activity
because of the inhibitory effect of pro-inflammatory
cytokines (IL-1b, IL-6, TNF-a) on cytochrome P450 [78].
On the contrary, it has been reported that in trauma
patients, especially if severe head injury is present, liver
metabolism of certain drugs (phenytoin, pentobarbital,
lorazepam) may be increased [53,79,80]. Modification of
portal vein flow, secondary to MV, could also decrease
hepatic metabolization rate of drugs, especially of high-
hepatic-extraction molecules, whereas clearance of low-
hepatic-extraction molecules is more dependent on liver
enzymatic capacity and free plasmatic drug fraction
[52,53].
In critically ill patients, drug interaction should always
be taken into account. Many classes of drugs, frequently
prescribed in ICU, exert an inhibitory effect on cyto-
chrome P450 [52,54,81]: proton-pump inhibitors used
to prevent stress-related gastrointestinal bleeding [82];
antiepileptic drugs, which are commonly used in patients
with head injury and documented electroencephalo-
graphic signs of secondary seizures [83]; antimicrobial
agents such as macrolides, fluoroquinolones, and azole
derivate antifungal agents [54,84]. Note that therapeutic
hypothermia, employed to decrease neurological damage
in patients recovering from a cardiac arrest, exert an
inhibitory effect on cytochrome P450 as well [85].
Renal excretion
The renal clearance of drugs can be severely impaired in
patients with sepsis, MT, cardiac failure, direct or
secondary (acute tubular necrosis, myoglobinuria) renal
injuries. Drug dose adjustments should be made to the
amount of serum creatinine and to the 24-h clearance
of creatinine. For antimicrobials (e.g., glycopeptides) or
sedative drugs (e.g., benzodiazepine), frequent deter-
minations of plasma concentrations are necessary.
Adjustment of daily dosage of antimicrobials is also
required in patients who undergo hemofiltration, like
continuous veno-venous hemofiltration (CVVH), based
on predicted drug CVVH removal rate [86,87].
Perfusion failure, capillary leakage and
modification of distribution volume
Peripheral ischemia/hypoxia in critically ill patients
produces a reduction in tissue pH and endothelium
damage. Tissue pH leans towards acidity largely because
of an increased anaerobic metabolism of the cells,
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following oxygen delivery failure, with glucose conversion
into ATP through the anaerobic glycolytic pathway, with
the production of lactic acid. The pharmacokinetic and
pharmacodynamicmodifications that follow a pH change,
have not been studied extensively. However, for drugs that
are weak acids, metabolic acidosis may determine an
increase in the not-ionized fraction, which, theoretically,
enhances drug diffusion through the cell membrane,
whereas the reverse phenomenonmay apply to drugs that
are chemically weak bases [52].
An increase in capillary permeability is primary
caused by endothelium damage. Because of plasma
extravasation, a large amount of fluids may be accumu-
lated into the interstitium and in anatomical spaces
usually fluid-free (third space). This phenomenon affects
the distribution of all drugs, especially of those with
small distribution volumes.
Perfusion failure and change in distribution volume
significantly affect the pharmacokinetic profile of several
classes of antibiotics, which play a pivotal role in the
pharmacological therapy of primary infections and
nosocomial contaminations. Estimation of distribution
volume is crucial to calculate appropriate loading and
maintenance dose. Several data indicate that the distri-
bution volume of antibacterial drugs most commonly
used in patients with SIRS or sepsis, is mainly related
with extracellular water, with the exception of fluor-
oquinolones [55], even though relevant pharmacoki-
netic differences within the same class of antibacterials
(e.g., carbapenems) have been described [88].
Time-dependent antimicrobial agents (e.g., beta-lac-
tams, glycopeptides, oxazolidinones) need to maintain
plasma concentrations higher than the minimum inhib-
itory concentration (MIC), to be more effective [89,90].
At the same time, concentration-dependent antimicro-
bial agents (e.g., aminoglycosides, fluoroquinolones)
should be administrated based on the ratio between the
area under curve (AUC) and the MIC, and the ratio
between plasma-peak concentration (Cmax) and the MIC
[89,90]. Therefore, daily determination of antimicrobial
plasma concentrations should be performed in critical
patients in which the pharmacokinetic determinants
(distribution volume, plasma protein, perfusion, kidney/
liver clearance) are so deeply altered.
Reduction in plasma protein radically changes the rate
of drug–protein binding. Increased capillary permeability,
hemodilution, and kidney failure, all contribute to the
diminution of circulating albumin fraction. Moreover, the
composition of plasma proteins is altered by the produc-
tion of acute phase reactant proteins, such as a1-acid
glycoprotein, with a profound effect on circulating drug–
protein binding [52].
The distribution curve and the biological availability of
drugs are also greatly influenced by body mass index
[91]. Indeed, obesity can alter both the volume of
distribution and the metabolism of antimicrobials, and
correction factors based on ‘actual’ body weight or ‘ideal’
body weight, depending on the drug, should be employed
[91–93]. Infusion dose of sedative drugs should also be
accurately adjusted in obese critically ill patients. The
sedative effects of propofol and benzodiazepines, such as
midazolam and its active metabolite, could be prolonged
because of their accumulation in adipose tissues [94].
Half-life modifications
The half-life of a sedative drug is one of the most
important criteria to guide the correct timing of MV and
weaning from ventilatory support. In the critical patient
who needs to be continuously sedated for variable
lengths of time, the half-life of a sedative molecule is
profoundly influenced by the duration of the infusion.
The observation of the sustained sedative effect, lasting
after the stop of the infusion, moved Hughes et al. in
1992 to develop the concept of context-sensitive half-life
(CSHL) [95,96]. CSHL should be considered as a ‘time-
to-recovery’ index after a prolonged infusion of a
sedative drug, where the context is the duration of the
infusion. This index is calculated based on a multi-
compartment model, but it is not directly related to the
half-life of the drug. This pharmacokinetic model is not
specific for the altered physiology of a critical patient,
but is particularly relevant in this context. Indeed, the
accumulation of drugs used for sedation (such as
propofol, midazolam, fentanyl) produces a prolongation
of the time to recovery, which cannot be predicted using
the half-life of the molecule, but it could be estimated
from the duration of the infusion, with a large inter-
individual variability.
CONCLUS IONS
Pharmacological management of an ICU patient remains
a challenge. At present, few evidence-based indications
are available. However, the following considerations
should always guide the physician who treats complex
and critical patients who need multiple drugs: obtain
plasma concentrations of drugs whenever possible;
consider the altered distribution volume especially when
hydrophilic antimicrobial agents are employed; monitor
IAP; closely screen hepatic and renal function; ensure an
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appropriate nutritional support. A closer collaboration
between the intensivists and the clinical pharmacologists
may improve, in the future, the efficacy of care for a
critically ill patient.
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